Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial

Background and objective:  Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4‐year COPD trial.

[1]  M. Decramer,et al.  Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. , 2010, Respiratory medicine.

[2]  M. Decramer,et al.  Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial , 2010, European Respiratory Journal.

[3]  M. Nishimura,et al.  Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. , 2010, Respiratory medicine.

[4]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[5]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[6]  M. Decramer,et al.  Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial , 2009, European Respiratory Journal.

[7]  N. Zhong,et al.  Trends in COPD mortality and hospitalizations in countries and regions of Asia‐Pacific , 2009, Respirology.

[8]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). , 2009, Revista portuguesa de pneumologia.

[9]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[10]  C. Lai,et al.  Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  N. Zhong,et al.  Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.

[12]  E. Burchard,et al.  Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  M. Cazzola,et al.  Review: Safety of long-acting β2 -agonists in the treatment of asthma , 2007, Therapeutic advances in respiratory disease.

[14]  E. Burchard,et al.  Ethnic-Specific Differences in Bronchodilator Responsiveness Among African Americans, Puerto Ricans, and Mexicans with Asthma , 2007, The Journal of asthma : official journal of the Association for the Care of Asthma.

[15]  T. Honda,et al.  Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high‐resolution computed tomography , 2006, Respirology.

[16]  N. Zhong,et al.  Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.

[17]  B. Yawn.  Beta2 agonists in the treatment of asthma. , 2006, American family physician.

[18]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[19]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[20]  E. Silverman,et al.  Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. , 2005, American journal of respiratory and critical care medicine.

[21]  N. Zhong,et al.  Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: An Asia–Pacific perspective , 2005, Respirology.

[22]  M. Nishimura,et al.  COPD in Japan: the Nippon COPD Epidemiology study , 2004, Respirology.

[23]  T. Kuriyama,et al.  Clinical phenotypes of COPD: Results of a Japanese epidemiological survey , 2004, Respirology.

[24]  Y. Nasuhara,et al.  Effect of low‐dose theophylline on airway inflammation in COPD , 2004, Respirology.

[25]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[26]  S. King.  Clinical trial design. , 1997, Seminars in interventional cardiology : SIIC.